An observational study in Cervical Spondylotic Myelopathy, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by University of California, San Francisco · Observational
Among 85 studies in Spinal Cord Diseases with a site in United States — 29 open to participants now, 35 under way, 1 of them phase 3. Spinal Cord Diseases · United States.
Among the 85 studies in Spinal Cord Diseases with a site in United States, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 9 that started in 2026, is one of 14 observational ones, reaches primary completion later than 29 of the 34 other live ones, and was the 84th registered.
170 studies on the registry are indexed under Spinal Cord Diseases; 56 are open to participants now.
Browse Spinal Cord Diseases studies →29 of the 85 studies in Spinal Cord Diseases with a site in United States are open now. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 50–90
University of Alabama at Birmingham · Sites in United States
Ages 18–89
Peter C. Gerszten, MD · Sites in United States
Ages 21–75 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18+ · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Spinal Cord Diseases studies recruiting now, 18 (56%) set no upper age limit and 6 (19%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 9 · Phase 4 1
First in 1993; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 45 observational studies indexed under Spinal Cord Diseases.
Median enrollment 30 across the 71 interventional studies, 86 across the 14 observational. Of the 43 that completed or were terminated, 22 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 85 have an industry lead sponsor. The 10 most frequent:
University of California, San Francisco is the lead sponsor of 2,170 studies on the registry; 370 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 203 (76%) have results posted.
University of California, San Francisco has 1 study filed under Spinal Cord Diseases — fewer than ten, so there is no comparison to draw.
12 of the studies in Spinal Cord Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03504826Brooks RehabilitationWalking Rehabilitation After Spinal Cord Injury: Locomotor Training Using Adaptive Robotics | 2026-12-31 |
| NCT05776030VA Office of Research and DevelopmentMulti-speed Ergonomic Wheelchair | 2026-12-31 |
| NCT06330181Texas A&M UniversityVirtual Walking Therapy for Neuropathic Pain Following Incomplete Spinal Cord Injury | 2027-04 |
| NCT07364773Shirley Ryan AbilityLabEnhancing Rehabilitation Participation in Patients With SCI/D Using Motivational Interviewing | 2027-04-20 |
| NCT07877766Hospital for Special Surgery, New YorkAssessing Microbiome in Primary Anterior Cervical Fusion Patients | 2027-05-20 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Spinal Cord Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigators believe that patients with cervical spondylotic myelopathy (CSM) have measurable changes in certain molecules in their blood compared with people without CSM. Investigators expect that these changes may be related to how severe a patient's condition is based on imaging and clinical exams. Investigators will also study how these molecules change before and after surgery to see whether they are related to how well patients recover. By combining these blood markers with clinical and imaging information, investigators hope to develop a tool that may help predict patient outcomes.
Cervical spondylotic myelopathy (CSM) represents the most common cause of non-traumatic spinal cord injury in adults (New et al., 2014) with an estimated prevalence of 605 per million in North America (Nouri et al., 2015). This degenerative condition leads to spinal cord compression which can result in severely debilitating symptoms such as weakness, loss of fine motor control, bowel and bladder dysfunction, and pain. Surgical decompression is often needed in patients with symptomatic neural element stenosis, and surgical decision-making is primarily based on clinical examination findings and imaging evidence of cervical spinal cord compression. However, the degree of spinal cord compression observed on imaging poorly correlates with the severity of neurologic dysfunction in cervical myelopathy patients (Nagata et al., 2012; Rhee et al., 2009). Additionally, there are no reliable objective measures or prognostic factors to aid in assessing patients best-suited for surgical decompression and recovery following surgery. This study aims to identify serum biomarkers of CSM injury severity and long-term outcomes. This proposal focuses on transcriptomic changes as well as radiographic and clinical data variables in CSM patients to characterize RNA biomarkers of injury and recovery, which has been studied to date. Identification of prognostic biomarkers of CSM may uncover new mechanisms underlying spinal cord injury and develop predictive algorithms for CSM treatment planning and prediction of long-term outcomes.
The study population will include patients with cervical spondylotic myelopathy (CSM) receiving care at the UCSF Spine Center. Participants will undergo standard-of-care treatment and follow-up at UCSF, with research blood samples collected before surgery and at designated postoperative timepoints. Clinical, imaging, medical history, and patient-reported outcome data will also be collected throughout the study.
Healthy Inclusion Criteria:
CSM Inclusion Criteria:
Healthy Exclusion Criteria:
CSM Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All Adults over age of 18, with a diagnosis of/encompassed by/related to cervical spondylotic myelopathy, cervical myelopathy, or ossification of posterior longitudinal ligament.
Adults over age of 18, with no neck pain, radiculopathy, or myelopathy symptoms, and no trauma in the past 6 months. Does not meet exclusion criteria.
Diagnostic performance of serum RNA biomarkers for CSM
Area under the receiver operating characteristic curve (AUC) comparing serum RNA biomarker levels in patients with CSM versus healthy controls
Time frame: Preoperative/baseline visit
Association between serum RNA biomarkers and radiographic CSM severity
Time frame: Preoperative/baseline visit
Association between serum RNA biomarkers and clinical CSM severity
CSM severity measured by clinical and sensorimotor examinations
Time frame: Preoperative visit through 2 years postoperatively
Association between serum RNA biomarkers and functional outcomes/recovery
Association between changes in candidate serum RNA biomarker levels and postoperative functional outcomes, including study questionnaires and sensorimotor examinations
Time frame: Preoperative, 6 weeks, 3 months, 6 months, 1 year, and 2 years postoperatively
Longitudinal change in serum RNA biomarkers
Time frame: Preoperative, 6 weeks, 3 months, 6 months, 1 year, and 2 years postoperatively
Plan to share: No
Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, San Francisco →